Visceral pain is defined as the pain that results from the nociceptors activation of the pelvic, thoracic or abdominal bowels (organs). The visceral structures are highly sensitive to stretch (distension), inflammation, and ischemia, but moderately insensitive to other stimuli that usually evoke pain such as burning or cutting. The symptoms of visceral pain are vomiting, nausea, changes in vital signs, and emotional manifestations. Pregabalin or gabapentin are some of the medications used for visceral pain treatment.
Key players are highly focused on research & development and partnership to produce novel drugs and treatments for various visceral pain. Moreover, companies are focusing on licensing agreements to capitalize the market opportunity with synergies.
For instance, in February 2020, Novartis AG and the Drugs for Neglected Diseases initiative (DNDi) jointly entered into a licensing agreement in order to co-develop ‘LXE408,’ which is a potential novel visceral leishmaniasis treatment. The Welcome Trust financially supported to discover LXE408 at Novartis, which is a first-in-class compound.
Request Here PDF Brochure Of This Report @ https://www.coherentmarketinsights.com/insight/request-pdf/4095
In March 2018, Arena Pharmaceuticals presented phase I and preclinical data on APD371 for produce pain treatment regarding the Crohn’s disease at the Annual Scientific Summit at American Pain Society. Olorinab or APD371 is an oral, peripherally acting, highly-selective discovered trial drug for the visceral pain treatment related to gastrointestinal disorders.
Visceral Pain Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
The COVID-19 outbreak has hugely affected the visceral pain treatment market, as patients with diseases such as Chron’s, IBS, and others are overlooked during the pandemic. The possibility of visceral abdominal pain has main implications in the clinical trials during the COVID-19 pandemic. The visceral infarction must be considered in disparity diagnosis when COVID-19 patients report severe abdominal pain. However, it is challenging for researchers and key players to perform clinical trials during this pandemic crisis. Conversely, various market players are involved in R&D activities to develop novel drugs & treatment for visceral pain.
Crohn’s disease is one of the most common indications of visceral pain and its incidence in the North America region comes out to be 400 to 600 cases per 100,000 people. According to the CDC (Centers for Disease Control and Prevention), more than 3 million people were diagnosed with IBD (irritable bowel disease) such as Crohn’s or ulcerative colitis in 2015.
Key Takeaways of the Global Visceral Pain Treatment Market:
- The global visceral pain treatment market is expected to exhibit a CAGR of 5.26% during the forecast period (2020-2027), due to the growing investments by pharmaceutical companies and governments for research and development
- Among indications, the irritable bowel syndrome segmentis likely to account for the largest revenue share by 2027, due to the rising number of irritable bowel syndrome (IBS) cases around the globe. For instance, according to the International Foundation for Gastrointestinal Disorders (IFFGD) in 2016, around 10-15% of the adult populations across the world are affected by IBS every year.
- Astellas Pharma Inc., Addex Therapeutics Ltd., Takeda, AstraZeneca, Chromocell Corporation, Allergan, GIcare Pharma Inc., Grunenthal GmbH, Abbvie, Johnson & Johnson, Medestea Research & Production S.p.A., and Neurim Pharmaceuticals Ltd.
Request Here For The Sample Copy Of The Report @ https://www.coherentmarketinsights.com/insight/request-sample/4095
Table of Content
Chapter 1 Industry Overview
1.3 Research Scope
1.4 Market Analysis by Regions
1.5 Visceral Pain Treatment Market Size Analysis from 2022 to 2028
11.6 COVID-19 Outbreak: Visceral Pain Treatment Industry Impact
Chapter 2 Global Visceral Pain Treatment Competition by Types, Applications, and Top Regions and Countries
2.1 Global Visceral Pain Treatment (Volume and Value) by Type
2.3 Global Visceral Pain Treatment (Volume and Value) by Regions
Chapter 3 Production Market Analysis
3.1 Global Production Market Analysis
3.2 Regional Production Market Analysis
Chapter 4 Global Visceral Pain Treatment Sales, Consumption, Export, Import by Regions (2017-2022)
Chapter 5 North America Visceral Pain Treatment Market Analysis
Chapter 6 East Asia Visceral Pain Treatment Market Analysis
Chapter 7 Europe Visceral Pain Treatment Market Analysis
Chapter 8 South Asia Visceral Pain Treatment Market Analysis
Chapter 9 Southeast Asia Visceral Pain Treatment Market Analysis
Chapter 10 Middle East Visceral Pain Treatment Market Analysis
Chapter 11 Africa Visceral Pain Treatment Market Analysis
Chapter 12 Oceania Visceral Pain Treatment Market Analysis
Chapter 13 South America Visceral Pain Treatment Market Analysis
Chapter 14 Company Profiles and Key Figures in Visceral Pain Treatment Business
Chapter 15 Global Visceral Pain Treatment Market Forecast (2022-2028)
Chapter 16 Conclusions
Direct Buy This Premium Research Report, Click Here @ https://www.coherentmarketinsights.com/insight/buy-now/4095
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Phone: US +12067016702 / UK +4402081334027